Overall rank by patents
#29,125
of 49,997 tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Inxmed ranks #29,125 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 5 technology areas.
USPTO PatentsView assignee plate
Corpus R29125 · Foreign Corporation #29,125 · 9 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Inteva France (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Inxmed (NANJING) · this assignee
43 score
3D Lighting… · lowest
7 score
What this shows Inxmed's Innovation Score is 43.5/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Inxmed (NANJING) Co., Ltd. is a focused PatentsView assignee: 5 CPC subclasses with 88.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (7 grants) versus a trough of 1 in 2022. By volume, Inxmed sits between Inteva France and IP Technology Labs, LLC.
Inxmed (NANJING) Co., Ltd. shows 8 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Inteva France
9 patents
Intex Holdings PTY Ltd
9 patents
INTiRiON Corporation
9 patents
Invetx, Inc.
9 patents
Ionian Technologies, LLC
9 patents
Ionics France
9 patents
IP GEM Group, LLC
9 patents
IP Technology Labs, LLC
9 patents
Inxmed (NANJING) Co., Ltd.
9 patents
What this shows Inxmed holds 9 patents at rank #29,068, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #29,068 in granted patent volume.
Other assignees with the most granted patents in Inxmed's primary technology class.
Inxmed's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
43 Top 28% higher than 72% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 11.1% |
| 2024 | 7 | 77.8% |
| 2025partial year | 1 | 11.1% |
Top 5 of 5 technology areas
Overall rank by patents
#29,125
of 49,997 tracked assignees
43.5 out of 100
What to do with this data
Inxmed (NANJING) Co., Ltd.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.